Coralan Experience (CORE) Survey - First Malaysian Experience of Ivabradine in Stable AnginaGim-Hooi Choo1*, Ahmad Nizar Jamaluddin1, David Kwang-Leng Quek2 and Tan Beng Hong2
- *Corresponding Author:
- Gim-Hooi Choo
Sime Darby Medical Centre Subang Jaya
1, Jln SS12/1, 47500 Subang Jaya
Selangor DE, Malaysia
E-mail: [email protected]
Received date: January 18, 2013; Accepted date: January 23, 2013; Published date: January 25, 2013
Citation: Choo GH, Jamaluddin AN, Leng DQK, Hong TB (2013) Coralan Experience (CORE) Survey – First Malaysian Experience of Ivabradine in Stable Angina. Pharmaceut Anal Acta 4:213.doi: 10.4172/2153-2435.1000213
Copyright: © 2013 Choo GH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aims: This non-randomised observational study primarily sought to evaluate the initial experiences with Ivabradine in these patients in terms of its efficacy in angina-related endpoints as well as highlighting safety issues, if any. This study also describes the profile of patients with stable angina pectoris. Methodology: Patients with angina pectoris and baseline HR above 70 bpm were recruited. Ivabradine 5 mg bd was added to baseline treatment, and further dose increment to 7.5 mg bd after 1 month if the HR remains above 70 bpm. Follow-up assessments were made at 2 time-points after initial recruitments i.e. after 1 and 2 months. Haemodynamic effects on blood pressure and HR were measured. Angina related parameters were assessed via patient interview. Safety issues were also reported. Results: 304 patients were recruited. There is a high prevalence of underlying hypertension (65.1%) and diabetes mellitus (46.4%). More than half (53.3) of the patients were already on baseline beta-blocker therapy. As expected, ivabradine use resulted in the significant reduction in HR from 81.7 ± 13.8 bpm to 67.0 ± 8.9 bpm without significant change in the BP measurements. All angina severity indicators e.g. number of angina episodes, use of short-acting nitrates and angina class improved. Side-effects were uncommon. This treatment was well tolerated and accepted by most patients. Conclusion: Ivabradine as a pure HR-reduction agent is an efficacious strategy for angina improvement with minimal concerns of safety and side-effects. This early experience of Ivabradine use and its effects in Malaysia was in concordance with currently available clinical evidence.